|
Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer
|
1R43CA213632-01
|
$231,500
|
WOLFSON, ALEXEY
|
ADVANCED RNA TECHNOLOGIES, LLC
|
|
The sequence recognition, structure and function of the IMP family of mRNA binding proteins
|
1F30CA214009-01A1
|
$49,044
|
BISWAS, JEETAYU
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
1F30CA210372-01A1
|
$49,044
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-02
|
$409,153
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Roles of formins in breast cancer invasion
|
5R21CA205262-02
|
$217,935
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Methylthioadenosine Phosphorylase and AdoMet Synthetase in Cancer
|
5R01CA135405-10
|
$290,592
|
SCHRAMM, VERN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Establishment of a patient-like mouse models of soft-tissue sarcoma sub-types
|
1R43CA213649-01
|
$224,700
|
HOFFMAN, ROBERT
|
ANTICANCER, INC.
|
|
AML-MutationCounter, a tool to detect residual and recurrent leukemia
|
1R41CA213690-01
|
$220,087
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-02
|
$44,044
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-04
|
$318,923
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression
|
5R21CA205257-02
|
$172,369
|
MCGUIRE, SEAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-12
|
$249,637
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Discovering genetic networks of triple-negative breast cancer
|
5R01CA178039-05
|
$324,738
|
WESTBROOK, THOMAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-04
|
$315,983
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Pharmacological modulation of epigenetic changes in AML
|
5R01CA102031-12
|
$342,107
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
MiR-199~214 cluster at the crossroads of plasticity and malignancy in breastcancer
|
1R01CA207322-01A1
|
$395,738
|
KARNOUB, ANTOINE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
1R44CA213595-01
|
$798,225
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Development of a novel cell-based immune therapy using Nanoparticles and natural IgM-producing phagocytic B cells
|
5R21CA205415-02
|
$186,807
|
ZHONG, XUEMEI
|
BOSTON MEDICAL CENTER
|
|
Co-targeting oncogenic pathways in advanced prostate cancer
|
5R01CA198097-02
|
$381,212
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Transforming the diagnosis and care of patients with CTCL using TCR sequencing
|
5R01CA203721-02
|
$680,545
|
CLARK, RACHAEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
|
5R01CA173610-05
|
$361,558
|
DIMITROFF, CHARLES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Pathogenesis and Treatment of NUT-Midline Carcinoma
|
5R01CA124633-10
|
$331,829
|
FRENCH, CHRISTOPHER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Physicians' Health Study II: Prevention Trial of Vitamins
|
5R01CA097193-07
|
$1,563,010
|
GAZIANO, J
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Selenoproteins as targets for cancer prevention
|
5R01CA080946-17
|
$316,004
|
GLADYSHEV, VADIM
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
CRISPR/Cas9-based lineage tracing for fate mapping of cancer cells and stem cells
|
5R21CA205825-02
|
$207,365
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
|
1R01CA207982-01A1
|
$411,278
|
WIDLUND, HANS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
tDCS for Increasing Exercise Adherence in Individuals with Elevated Depressive Symptoms
|
1R21CA214102-01A1
|
$185,963
|
ABRANTES, ANA
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
Simultaneous Detection of Proteins and Whole Transcriptomes in Single Cells
|
1F32CA213966-01
|
$56,694
|
XU, ALEXANDER
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Targeting Brain Tumor Stem Cells In The Hypoxic Microenvironment
|
5R01CA187780-03
|
$385,491
|
BAR, ELI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
BORG: Role for a Novel lncRNA in Mediating Breast Cancer Metastasis and Dormancy
|
5F30CA203233-02
|
$49,044
|
GOODING, ALEX
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case/UHC Center for AIDS Research
|
P30AI036219-23
|
$229,791
|
KARN, JONATHAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
15-Hydroxyprostaglandin Dehydrogenase, NSAIDs, Vitamin D, and Coloretcal Neoplasi
|
5U01CA181770-04
|
$507,599
|
LI, LI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining the role of the PR72 regulatory subunit in small molecule mediated activation of PP2A's tumor suppressive activity
|
1F31CA213554-01
|
$37,644
|
PERL, ABBEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
SLX4IP and a novel regulatory network in breast cancer metastasis and dormancy
|
1F30CA213892-01
|
$44,044
|
ROBINSON, NATHANIEL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanisms of suppression of colon cancer by receptor tyrosine phosphatase PTPRT
|
5R01CA127590-10
|
$292,112
|
WANG, ZHENGHE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
|
1R41CA213463-01
|
$300,000
|
SZABO, CSABA
|
CBS THERAPEUTICS, INC.
|
|
Omics Approach to Interrogating Mechanism of ETV5 in Glioma
|
1F31CA213926-01
|
$37,644
|
PARK, HANNAH
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-10
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Myc - miR-17-92 axis in colorectal cancers
|
5R01CA196299-03
|
$384,300
|
THOMAS-TIKHONENKO, ANDREI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-10
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Bench to bedside: non-invasive treatment of tumors in children
|
1U01CA202947-01A1
|
$350,585
|
KIM, PETER
|
CHILDREN'S RESEARCH INSTITUTE
|
|
2017 Cholangiocarcinoma Foundation Annual Conference
|
1R13CA213778-01
|
$5,000
|
LINDSEY, STACIE
|
CHOLANGIOCARCINOMA FOUNDATION
|
|
Patient Preferences and Adherence in Adolescents and Young Adults with Cancer
|
5K07CA200668-02
|
$144,855
|
MCGRADY, MEGHAN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Hemostatic Factors Drive Prostate Cancer Pathogenesis
|
5R01CA193678-02
|
$356,850
|
PALUMBO, JOSEPH
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Coagulation factors as modifiers of the colon cancer microenvironment
|
5R01CA204058-02
|
$356,850
|
PALUMBO, JOSEPH
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting Ferritin in Glioblastoma
|
5R01CA169117-05
|
$532,477
|
BAO, SHIDENG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Microenvironment Interleukin-17 and Colorectal Cancer Treatment Resistance
|
5R01CA193359-03
|
$362,569
|
KALADY, MATTHEW
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting TCA cycle in Brain Tumor Initiating Cells
|
5F30CA203101-02
|
$35,252
|
KIM, JIN YOUNG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Serotonin drives cancer stem cell maintenance and glioblastoma progression
|
1F32CA213727-01
|
$60,990
|
SILVER, DANIEL
|
CLEVELAND CLINIC LERNER COM-CWRU
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|